Silent infarction on a second CT scan in 91 patients without manifest stroke in the Dutch TIA trial.
The frequency of silent infarction is an important issue because it is a marker of vascular disease. We studied the occurrence of silent infarction in a sample of patients from the Dutch TIA trial, in which patients were randomized between 30 and 283 mg of aspirin. A total of 91 patients with TIA or non-disabling ischemic stroke and who did not suffer a stroke during a period of one to four years (mean 32 months) underwent CT scanning both on entry and at the end of the study. A cardiac source of embolism was an exclusion criterion for the trial. We found only one patient with a possibly silent infarction; in four patients a previously detected symptomatic infarct on CT was no longer visible. The rarity of silent infarction in this study may have several explanations; (1) the relatively short period of follow-up, (2) the selection of patients (no cardiac source of embolism), (3) the clinical monitoring at four monthly intervals aimed at detection of focal ischemia, (4) the use of aspirin. Given these circumstances, silent infarction is an infrequent problem.
Herderscheê
D
D
Department of Neurology, Academisch Medisch Centrum, Amsterdam, The Netherlands.
Hijdra
A
A
Algra
A
A
Kappelle
L J
LJ
Koudstaal
P J
PJ
van Gijn
J
J
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D001262:Atenolol / Q000008:administration & dosage / Q000627:therapeutic use; D002544:Cerebral Infarction / Q000175:diagnosis* / Q000503:physiopathology; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011699:Putamen / Q000503:physiopathology; D012307:Risk Factors; D014057:Tomography, X-Ray Computed
D001262:Atenolol; D001241:Aspirin